Stem Cell-based Vaccine may Protect Against Pancreatic Cancer

Vaccine made from pluripotent stem cells (iPSCs) offers a new approach that may protect against pancreatic cancer, said researchers.

The stem cells produce a large set of antigens that have overlap to a specific type of pancreatic cancer and that these similarities can be used for potential clinical benefit.

Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.

‘The iPSC-based vaccine targets many cancer antigens simultaneously, this vaccination approach may be more durable as pancreatic tumor cells may be left with fewer ways of escaping recognition by the vaccine-trained immune system.’

It is well known that vaccines can be highly effective in preventing infections by training the immune system to recognize agents foreign to the body, such as viruses, and to eliminate them. Vaccines trigger the immune system by presenting so-called antigens, such as proteins not normally present in the body, which are then recognized as foreign by the immune system and therefore trigger an immune response.

Less known, and still in the early stages, are vaccines against cancer. Tumor cells often contain unique antigens that are rare or not found in other tissues of the body and, like antigens from a virus, can be targets for the immune system.

To date, it has been a challenge to develop an effective and durable (lasting) vaccine against tumors. In this study, recently published in Stem Cell Reports, the researchers capitalized on the knowledge that iPSCs produce antigens that are also found on different types of tumors, but not present in most normal tissue.

Quiz on Pancreatic Cancer
Pancreatic cancer is often diagnosed at a late stage and can be fatal. Test your knowledge on pancreatic cancer by taking this quiz.

They then vaccinated mice with the iPSCs that were treated with irradiation, so that they would not divide, and a CpG adjuvant to stimulate a robust immune response. Their hope was to train the mice's immune systems to mount a response against the iPSCs, or any type of cell with a similar antigen makeup, including cancer cells.

The results of the study are insightful. The iPSC vaccination protected 75% of mice subsequently injected with pancreatic cancer cells from developing tumors. Further, vaccination increased the number of tumor-targeting immune cells, and the vaccinated mice developed antibodies against the cancer cells.

Surgery is Viable Treatment for Pancreatic Cancer Patients Post-chemotherapy
Patients with stage II pancreatic cancer who receive chemotherapy followed by resection live nearly twice as long as patients who receive only chemotherapy.

What's more, this strategy may also work for other cancer types with similar antigen makeup to iPSCs. Further studies are required to show if iPSC cancer vaccines are safe and effective in patients, both in preventing tumor growth or re-growth and in eliminating established tumors.

Source-Eurekalert

How Genes, Environment Play Role in Pancreatic Cancer Identified
Researchers in Scott Lowe's lab at the Sloan Kettering Institute are trying to inhibit the development of pancreatic cancer in the earliest stages.